Implicity Simplifies In-Clinic Cardiac RPM Workflows with New InLink Solution In-clinic tool automatically and securely links manufacturer programmers with Implicity’s data management solution for faster, more efficient remote monitoring workflows Cambridge, Mass., April 18, 2023 – Implicity, a leader in remote patient monitoring and cardiac data management solutions, introduced the immediate availability of InLink, a new in-clinic tool that streamlines remote cardiac monitoring workflows. Rather than having to use a USB thumb drive, InLink enables fast, secure wireless connections between the manufacturer programming systems for various cardiac implantable electronic devices (CIEDs) and the Implicity platform – making data exchanges faster, safer and more efficient. “InLink provides direct access to data and diagnostics collected by manufacturer programming systems during in-clinic device checks, eliminating the need for cumbersome manual data transfers and reducing security risks posed by USBs, such as ransomware. The transmissions now happen automatically, saving clinicians valuable time they can dedicate back to patient care,” said Ad́élie Cerrato, Product Manager at Implicity. Cardiology practices must provide routine in-clinic checks for patients with CIEDs (e.g., pacemakers, ILRs, defibrillators). During visits, remote patient monitoring (RPM) devices are interrogated by manufacturer programming systems (Medtronic, Boston Scientific, Abbott, Biotronik, Microport) to retrieve discrete data and diagnostic reports, test the device, and make necessary setting adjustments. All of that information then needs to be transferred into Implicity’s cardiac remote monitoring software or electronic medical record (EMR) systems. Previously, the reports had to be printed or downloaded onto a portable USB thumb drive. InLink modernizes this tedious process by allowing the systems to communicate and transfer data automatically. What’s more, InLink makes it easy to create in-clinic reports and access manufacturer PDFs at the end of each patient visit. “When you consider some cardiac clinics seeing over 50 patients daily, the benefits of InLink are substantial. The tool will easily save clinicians hours each week and liberate them from manual, repetitive tasks,” added Dr. Arnaud Rosier, CEO, and founder of Implicity. “This is yet another example of Implicity delivering innovative, practical solutions that help unify RPM workflows, improve the lives of clinicians and enable better, more effective cardiac care.” About ImplicityImplicity is a MedTech software company dedicated to providing the best remote care to patients with connected cardiac implantable electronic devices. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, our platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for those with chronic heart failure conditions. As the first and only cardiac implant remote monitoring company to receive FDA clearance for an AI-based algorithm, Implicity’s platform provides critical health information, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 80,000 patients in over 150 medical facilities across the US and Europe. To learn more, visit wwww.implicity.com Implicity®, Inc., is a Delaware corporation with offices located at 185 Alewife Brook Pkwy 210, Cambridge, MA 02138 USA, file number 5917973. * Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Implicity Introduces New Algorithm to Address Alert Fatigue in AF Care New feature tackles atrial fibrillation burden, reducing the alerts for patients being treated with anticoagulant medication and highlighting clinically significant events. Cambridge, Mass., April 12, 2023 – Implicity, a leader in remote patient monitoring and cardiac data management solutions, introduced a new algorithm designed to reduce alert fatigue in the remote monitoring of patients with atrial fibrillation (AF). Implicity’s AF Alert Management feature addresses AF burden, reducing alerts for patients who are taking anticoagulants and have a low risk of complications while triggering notifications the relevant moment there is a significant change in a patient’s condition that requires intervention or adjustments to treatment. “The AF Alert Management tool optimizes AFib burden management, allowing providers to focus on clinically significant events,” said Adélie Cerrato, Product Manager at Implicity. “AFib burden can vary greatly between individuals on anticoagulants or those who are not. Our new algorithm can differentiate between the two, quieting alerts associated with patients on medication and notifying providers with smart alerts when the burden exceeds the threshold for action. This, in turn, can lead to better patient outcomes as they receive appropriate care when needed.” Continuous remote monitoring is critical for properly managing patients with AF. It allows providers to track patients’ heart rhythms for early intervention and treatment, reducing complications such as stroke and heart failure. The AF burden rate, or percentage of time spent in an irregular heartbeat state, is measured using various devices, such as Holter monitors, pacemakers, defibrillators, and implantable loop recorders (ILRs). Implicity’s algorithm works with any device that collects atrial burden trends data and can classify the following scenarios in line with ESC recommendations: Consider proposing therapies to the patient, such as ablation: Paroxysmal AF Increasing paroxysmal AF Persistent AF Evaluates the success of therapies: Back to sinus rhythm Back to paroxysmal AF On average, cardiologists receive about 1,000 manufacturer’s alerts on atrial burden/month per every 1,000 patients. Reviewing these alerts manually can prove to be time-consuming and inefficient. Implicity’s AF Alert Management alleviates this pain point and has the potential to save hours of time each month, freeing up clinicians so they can focus on patient care. About ImplicityImplicity is a MedTech software company dedicated to providing the best remote care to patients with connected cardiac implantable electronic devices. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, our platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for those with chronic heart failure conditions. As the first and only cardiac implant remote monitoring company to receive FDA clearance for an AI-based algorithm, Implicity’s platform provides critical health information, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 80,000 patients in over 150 medical facilities across the US and Europe. To learn more, visit www.implicity.com * Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Implicity Releases SMART on FHIR App New feature tackles atrial fibrillation burden, reducing the alerts for patients being treated with anticoagulant medication and highlighting clinically significant events. Cambridge, Mass., April 12, 2023 – Implicity, a leader in remote patient monitoring and cardiac data management solutions, introduced a new algorithm designed to reduce alert fatigue in the remote monitoring of patients with atrial fibrillation (AF). Implicity’s AF Alert Management feature addresses AF burden, reducing alerts for patients who are taking anticoagulants and have a low risk of complications while triggering notifications the relevant moment there is a significant change in a patient’s condition that requires intervention or adjustments to treatment. “The AF Alert Management tool optimizes AFib burden management, allowing providers to focus on clinically significant events,” said Adélie Cerrato, Product Manager at Implicity. “AFib burden can vary greatly between individuals on anticoagulants or those who are not. Our new algorithm can differentiate between the two, quieting alerts associated with patients on medication and notifying providers with smart alerts when the burden exceeds the threshold for action. This, in turn, can lead to better patient outcomes as they receive appropriate care when needed.” Continuous remote monitoring is critical for properly managing patients with AF. It allows providers to track patients’ heart rhythms for early intervention and treatment, reducing complications such as stroke and heart failure. The AF burden rate, or percentage of time spent in an irregular heartbeat state, is measured using various devices, such as Holter monitors, pacemakers, defibrillators, and implantable loop recorders (ILRs). Implicity’s algorithm works with any device that collects atrial burden trends data and can classify the following scenarios in line with ESC recommendations: Consider proposing therapies to the patient, such as ablation: Paroxysmal AF Increasing paroxysmal AF Persistent AF Evaluates the success of therapies: Back to sinus rhythm Back to paroxysmal AF On average, cardiologists receive about 1,000 manufacturer’s alerts on atrial burden/month per every 1,000 patients. Reviewing these alerts manually can prove to be time-consuming and inefficient. Implicity’s AF Alert Management alleviates this pain point and has the potential to save hours of time each month, freeing up clinicians so they can focus on patient care. About ImplicityImplicity is a MedTech software company dedicated to providing the best remote care to patients with connected cardiac implantable electronic devices. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, our platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for those with chronic heart failure conditions. As the first and only cardiac implant remote monitoring company to receive FDA clearance for an AI-based algorithm, Implicity’s platform provides critical health information, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 80,000 patients in over 150 medical facilities across the US and Europe. To learn more, visit www.implicity.com * Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Implicity to Participate in Health Tech Challengers Super Finals at the HLTH 2022 Company named a Top 8 Super Finalist in the global health tech competition identifying the most disruptive companies shaping the future of digital health. Cambridge, Mass., November 8, 2022 – Implicity®, a leader in remote patient monitoring and cardiac data management solutions, announced it has been selected to participate in the Health Tech Challengers (HTC) Super Finals taking place live at HLTH 2022. The global competition identifies top companies fostering digital health innovation. Implicity won the Cardiovascular track and is one of only eight startups invited to pitch in-person at the live event in Las Vegas on November 15, 2pm at Venetian Ballroom D, Lvl 2, where the ultimate winner will be announced. “We’re honored to be among such an impressive group of finalists. This recognition validates the positive impact our AI-powered platform is having on cardiologists and healthcare professionals who care for patients with CIEDs. These remote cardiac monitoring solutions are producing more and more data each year. The only way for clinicians to process it all is with artificial intelligence-based tools. We are proud to deliver a solution to the market that can improve day-to-day life for practitioners, and allow them to spend more time with their patients,” said Dr. Arnaud Rosier, electrophysiologist, CEO, and co-founder of Implicity. Implicity’s AI algorithm that analyzes ECG data from implantable loop recorders (ILRs) received clearance from the Food and Drug Administration in late 2021. Earlier this year, the company announced $23M in Series A funding to accelerate expansion in the US and support the development of next-generation offerings that move toward the prevention of heart disease. Health Tech Challenger finalists were selected by a distinguished panel of industry experts from leading corporations, Venture Capital, ecosystem builders, and media partners. For more on the competition, visit: ​​https://healthtechchallengers.com/#TOP8   About Implicity Implicity® is a MedTech software company, cofounded by cardiac electrophysiologist Arnaud Rosier MD, that provides a universal cardiac remote monitoring and research platform to clinics and service companies – helping them provide the best remote care to cardiac patients. Implicity develops unique AI and knowledge-based algorithms with the potential to predict patient health status, which reduce the workload on healthcare professionals. The Implicity platform aggregates, normalizes, and standardizes data from all implantable cardiac electronic devices across all major manufacturers and improves care for patients with chronic heart failure conditions. Implicity proudly protects more than 70,000 patients in 150+ medical facilities across the United States and Europe.     Media Contact: Samantha Choinski eMedia Junction  860-301-5058 samantha@emediajunction.com